Uncategorized
Novaliq Announces Positive Topline Results for Its CyclASol® Phase 2B/3 Essence Trial in Patients with Dry Eye Disease
HEIDELBERG, Germany--(BUSINESS WIRE)--#AFT--Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces positive topline results from ESSENCE, its first pivotal clinical trial of CyclASol® 0.1% for the treatment of dry eye disease (DED). CyclASol® 0.1% is a preservative-free ophthalmic solution of 0.1% cyclosporine A in EyeSol® develo